


## Pilaralisib analogue

|                           |  |       |         |
|---------------------------|--|-------|---------|
| <b>Cat. No.:</b>          | HY-11105   |       |         |
| <b>CAS No.:</b>           | 956958-53-5  |       |         |
| <b>Molecular Formula:</b> | C <sub>21</sub> H <sub>16</sub> N <sub>6</sub> O <sub>2</sub> S <sub>2</sub> |       |         |
| <b>Molecular Weight:</b>  | 448.52   |       |         |
| <b>Target:</b>            | PI3K; Apoptosis  |       |         |
| <b>Pathway:</b>           | PI3K/Akt/mTOR; Apoptosis   |       |         |
| <b>Storage:</b>           | Powder   | -20°C | 3 years |
|                           |  | 4°C   | 2 years |
|                           | In solvent   | -80°C | 2 years |
|                           |  | -20°C | 1 year  |



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 50 mg/mL (111.48 mM)  
 \* "≥" means soluble, but saturation unknown.

| Concentration             | Solvent | Mass      |            |            |
|---------------------------|---------|-----------|------------|------------|
|                           |         | 1 mg      | 5 mg       | 10 mg      |
| Preparing Stock Solutions | 1 mM    | 2.2296 mL | 11.1478 mL | 22.2956 mL |
|                           | 5 mM    | 0.4459 mL | 2.2296 mL  | 4.4591 mL  |
|                           | 10 mM   | 0.2230 mL | 1.1148 mL  | 2.2296 mL  |

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (5.57 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Pilaralisib analogue (XL147 analogue) is a representative and selective PI3Kα inhibitor extracted from patent WO2012006552A1, Compound 147 in Table 1.

#### IC<sub>50</sub> & Target

PI3K-alpha

---

## CUSTOMER VALIDATION

- Cell Syst. 2020 Jan 22;10(1):66-81.e11.
- Harvard Medical School LINCS LIBRARY

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

[1]. Carlos L. Arteaga, et al. Combinations of kinase inhibitors for the treatment of cancer. WO 2012006552 A1.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA